19F magnetic resonance imaging of endogenous macrophages in inflammation

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 4, Issue 3, 2012, Pages 329-343

  Temme, Sebastian ^a   Bönner, Florian ^a   Schrader, Jürgen ^a   Flögel, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEGREE OF SPECIFICITY; HOT SPOT; IN-VIVO; MONOCYTES/MACROPHAGES; MRI (MAGNETIC RESONANCE IMAGING); PERFLUOROCARBONS; SIGNAL INTENSITIES; SIMULTANEOUS ACQUISITION; THERAPEUTIC INTERVENTION; TISSUE INFLAMMATION;

EMULSIFICATION; FLUORINE; MACROPHAGES; MAGNETIC RESONANCE IMAGING; TISSUE;

PATHOLOGY;

FLUORINE; FLUOROCARBON; FLUORODEOXYGLUCOSE F 18; LIPID EMULSION; NANOPARTICLE; PERFLUORO 15 CROWN 5 ETHER; PERFLUORODECALIN; PERFLUOROOCTYL BROMIDE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL LABELING; DENSITY GRADIENT CENTRIFUGATION; DRUG HALF LIFE; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MACROPHAGE; MONOCYTE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND; ANIMAL; BIOLOGICAL MODEL; CELL TRACKING; FLOW CYTOMETRY; METHODOLOGY; PATHOLOGY; REVIEW;

ANIMALS; CELL TRACKING; FLOW CYTOMETRY; FLUORINE; FLUOROCARBONS; HUMANS; INFLAMMATION; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL;

EID: 84864742335     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1163     Document Type: Article

References (104)

1. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-37.
2. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
3. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005, 23: 901-944.
4. You Y, Myers RC, Freeberg L, Foote J, Kearney JF, Justement LB, Carter RH. Marginal zone B cells regulate antigen capture by marginal zone macrophages. J Immunol 2011, 186:2172-2181.
5. Backer R, Schwandt T, Greuter M, Oosting M, Jungerkes F, Tuting T, Boon L, O'Toole T, Kraal G, Limmer A, et al. Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc Natl Acad Sci U S A 2010, 107:216-221.
6. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
7. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukoc Biol 2001, 70:163-170.
8. Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol 1984, 2:395-428.
9. Mahdavian DB, van der Veer WM, van Egmond M, Niessen FB, Beelen RH. Macrophages in skin injury and repair. Immunobiology 2011, 216:753-762.
10. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarizedM2mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
11. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
12. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton IJ, van RN, Alexander KA, Raggatt LJ, et al Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010, 116:4815-4828.
13. Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia 2011, 59:177-187.
14. Cyster JG. B cell follicles and antigen encounters of the third kind. Nat Immunol 2010, 11:989-996.
15. Phan TG, Green JA, Gray EE, Xu Y, Cyster JG. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol 2009, 10:786-793.
16. MacLennan IC. Germinal centers. Annu Rev Immunol 1994, 12:117-139.
17. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010, 234:120-141.
18. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J ExpMed 1985, 161:526-546.
19. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med 1968, 128: 415-435.
20. van Furth R, Thompson J. Review of the origin and kinetics of the promonocytes, monocytes, and macrophages and a brief discussion of the mononuclear phagocyte system. Ann Inst Pasteur (Paris) 1971, 120:337-355.
21. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, Weissman IL, Cyster JG, Engleman EG. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002, 3:1135-1141.
22. Kanitakis J, Petruzzo P, Dubernard JM. Turnover of epidermal Langerhans' cells. N Engl JMed 2004, 351:2661-2662.
23. Geissmann F. The origin of dendritic cells. Nat Immunol 2007, 8:558-560.
24. Fogg DK, Sibon C, Miled C, Jung S, Aucouturier P, Littman DR, Cumano A, Geissmann F. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 2006, 311:83-87.
25. Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol 2010, 17:53-59.
26. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinctmigratory properties. Immunity 2003, 19:71-82.
27. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
28. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661.
29. Qu C, Edwards EW, Tacke F, Angeli V, Llodra J, Sanchez-Schmitz G, Garin A, Haque NS, Peters W, van Rooijen N, et al. Role of CCR8 and other chemokine pathways in the migration of monocytederived dendritic cells to lymph nodes. J Exp Med 2004, 200:1231-1241.
30. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J ExpMed 2007, 204:3037-3047.
31. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007, 81:584-592.
32. Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and inflammation. CellMol Life Sci 2010, 67:2685-2693.
33. Shiozawa S, Tsumiyama K, Yoshida K, Hashiramoto A. Pathogenesis of joint destruction in rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 2011, 59:89-95.
34. Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009, 206:1839-1843.
35. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011, 6: 275-297.
36. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T. Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm 2010, 117: 961-970.
37. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011, 41:2522-2525.
38. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011, 121: 2111-2117.
39. Matoba T, Egashira K. Anti-inflammatory gene therapy for cardiovascular disease. Curr Gene Ther 2011, 11:442-446.
40. Seneviratne AN, Sivagurunathan B, Monaco C. Tolllike receptors and macrophage activation in atherosclerosis. Clin Chim Acta 2012, 413:3-14.
41. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999, 11:753-761.
42. Miller JC, Thrall JH. Clinical molecular imaging. J Am Coll Radiol 2004, 1:4-23.
43. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, et al. In vivo 18Ffluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818-1824.
44. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007, 13:636-641.
45. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990, 175:489-493.
46. Kleinschnitz C, Bendszus M, Frank M, Solymosi L, Toyka KV, Stoll G. In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J Cereb Blood Flow Metab 2003, 23:1356-1361.
47. Kok MB, Hak S, Mulder WJ, van der Schaft DW, Strijkers GJ, Nicolay K. Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. Magn Reson Med 2009, 61:1022-1032.
48. 19F magnetic resonance imaging. J Magn Reson 1977, 28: 133-136.
49. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr Med Chem 2005, 12:819-848.
50. 19F) MRS and MRI in biomedicine. NMR Biomed 2011, 24:114-129.
51. Bulte JW. Hot spot MRI emerges from the background. Nat Biotechnol 2005, 23:945-946.
52. Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. WIREs Nanomed Nanobiotechnol 2009, 1:492-501.
53. Krafft MP, Riess JG. Chemistry, physical chemistry, and uses of molecular fluorocarbon-hydrocarbon diblocks, triblocks, and related compounds -unique "apolar"components for self-assembled colloid and interface engineering. Chem Rev 2009, 109: 1714-1792.
54. Hammerschmidt DE, Vercellotti GM. Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations. Biomater Artif Cells Artif Organs 1988, 16:431-438.
55. Ingram DA, Forman MB, Murray JJ. Activation of complement by Fluosol attributable to the pluronic detergent micelle structure. J Cardiovasc Pharmacol 1993, 22:456-461.
56. Westesen K, Wehler T. Investigation of the particle size distribution of a model intravenous emulsion. J PharmSci 1993, 82:1237-1244.
57. Rotenberg M, Rubin M, Bor A, Meyuhas D, Talmon Y, Lichtenberg D. Physico-chemical characterization of Intralipid emulsions. Biochim Biophys Acta 1991, 1086:265-272.
58. Riess JG. Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2006, 34:567-580.
59. Spahn DR. Blood substitutes. Artificial oxygen carriers: perfluorocarbon emulsions. Crit Care 1999, 3: R93-R97.
60. Mattrey RF, Long DM, Multer F, Mitten R, Higgins CB. Perfluoroctylbromide: a reticuloendothelialspecific and tumor-imaging agent for computed tomography. Radiology 1982, 145:755-758.
61. Smith DJ, Kornbrust ES, Lane TA. Phagocytosis of a fluorescently labeled perflubron emulsion by a human monocyte cell line. Artif Cells Blood Substit Immobil Biotechnol 1994, 22:1215-1221.
62. 19F MRI in vivo. Circ Cardiovasc Imaging 2010, 3:202-210.
63. Flögel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, Schubert R, Schrader J. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008, 118:140-148.
64. 19F MRI in the early stage. Am J Transplant 2011, 11:235-244.
65. 19F-magnetic resonance imaging (MRI). PLoS One 2011, 6:e18246.
66. 19F magnetic resonance imaging. Invest Radiol 1988, 23:361-364.
67. Bratton DL, Henson PM. Neutrophil clearance: when the party is over, clean-up begins. Trends Immunol 2011, 32:350-357.
68. Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J ExpMed 2006, 203:583-597.
69. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 2011, 23:12-20.
70. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med 2007, 58:725-734.
71. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005, 23:983-987.
72. van den Bos EJ, Wagner A, Mahrholdt H, Thompson RB, Morimoto Y, Sutton BS, Judd RM, Taylor DA. Improved efficacy of stem cell labeling for magnetic resonance imaging studies by the use of cationic liposomes. Cell Transplant 2003, 12:743-756.
73. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999, 50: 507-529.
74. Waiczies H, Lepore S, Janitzek N, Hagen U, Seifert F, Ittermann B, Purfurst B, Pezzutto A, Paul F, Niendorf T, et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One 2011, 6:e21981.
75. Bucala R, Kawakami M, Cerami A. Cytotoxicity of a perfluorocarbon blood substitute to macrophages in vitro. Science 1983, 220:965-967.
76. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007, 21:1647-1654.
77. Caiazza S, Fanizza C, Ferrari M. Fluosol 43 particle localization pattern in target organs of rats. An electron microscopy study. Virchows Arch A Pathol Anat Histopathol 1984, 404:127-137.
78. Riess JG. Oxygen carriers ("blood substitutes")- raison d'etre, chemistry, and some physiology. Chem Rev 2001, 101:2797-2920.
79. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
80. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
81. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994, 22: 1043-1054.
82. Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A 2006, 78:620-628.
83. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J PharmSci 1995, 84:493-498.
84. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478.
85. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factoralpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci 2006, 27:27-36.
86. 19F NMR imaging of liver, tumor, and abscess in rats. Preliminary results. Invest Radiol 1985, 20:141-145.
87. Sotak CH, Hees PS, Huang HN, Hung MH, Krespan CG, Raynolds S. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med 1993, 29:188-195.
88. Noth U, Morrissey SP, Deichmann R, Jung S, Adolf H, Haase A, Lutz J. Perfluoro-15-crown-5-ether labelled macrophages in adoptive transfer experimental allergic encephalomyelitis. Artif Cells Blood Substit Immobil Biotechnol 1997, 25:243-254.
89. 19F MRI detection of acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. Magn Reson Med 2011, 65:1144-1153.
90. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005, 6:1182-1190.
91. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
92. Kennedy AD, DeLeo FR. Neutrophil apoptosis and the resolution of infection. Immunol Res 2009, 43: 25-61.
93. Keipert PE. Use of Oxygent, a perfluorochemicalbased oxygen carrier, as an alternative to intraoperative blood transfusion. Artif Cells Blood Substit Immobil Biotechnol 1995, 23:381-394.
94. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv Drug Deliv Rev 2001, 47:209-228.
95. 19F magnetic resonance imaging of perfluorooctylbromide. Magn Reson Med 2010, 63:1119-1124.
96. Morawski AM, Lanza GA, Wickline SA. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol 2005, 16:89-92.
97. 19F NMR study of perfluorodecalin. Org Magn Reson 1983, 21:397-398.
98. Kong CF, Holloway GM, Parhami P, Fung BM. C-13 and F-19 nuclear magnetic resonance study of perfluoro chemical emulsions. J Phys Chem 1984, 88: 6308-6311.
99. Rogers IS, Tawakol A. Imaging of coronary inflammation with FDG-PET: feasibility and clinical hurdles. Curr Cardiol Rep 2011, 13:138-144.
100. Bomanji J, Almuhaideb A, Zumla A. Combined PET and X-ray computed tomography imaging in pulmonary infections and inflammation. Curr Opin Pulm Med 2011, 17:197-205.
101. Stoll G, Bendszus M. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience 2009, 158:1151-1160.
102. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging 2007, 26:452-459.
103. 19F imaging agents. Magn Reson Med 2011, 66:1116-1122.
104. Schwitter J. Extending the frontiers of cardiac magnetic resonance. Circulation 2008, 118:109-112.